๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Astellas Pharma Inc. (TYO:4503)
Japan flag Japan ยท Delayed Price ยท Currency is JPY
2,725.00
-5.00 (-0.18%)
Nov 18, 2026, 3:30 PM JST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

FY26 guidance rose, with the 30% core operating profit margin target advanced to FY26. The five-year strategy backs strategic brands, pipeline investment and new clinical programs, while VYLOY and PADCEV-KEYTRUDA advance franchise growth.

Moderator

I think we should get started. My name is Steve Barker, pharma analyst from Jefferies in Japan, and it is my pleasure to introduce Astellas. We have the CEO, Naoki Okamura-san, and we also have Head of Commercial and Medical Affairs, Claus Zieler. I think you have some slides, so over to you, Dr. Okamura-san.

Naoki Okamura
CEO, Astellas

Thank you for the introduction, Steve. Very nice to meet you guys. My name is Naoki Okamura, CEO of Astellas, and let me walk you through a summary of our Corporate Strategic Plan 2026, which is the five-year plan for the coming five years, and some of the updates for the second quarter of this fiscal year. Oops. We have a vision that says, "Turning innovative science into value for patients." And we clearly define the value, which is used all capital letters of value, which is the outcomes that truly matter to patients on the numerator side, and denominator is the costs for the entire healthcare system to deliver those outcomes. We, of course, we are pharmaceutical companies, we are pursuing better outcomes, but in the sustainable way to the society.

That is the value definition that we have, and that is always at the core of all the decision-making for the company. At a glance, Astellas is based in Tokyo, but more than 85% of the revenue comes from outside of Japan. We are truly global company. The biggest market is the U.S., which represents almost 45% of our revenue. We are delivering very innovative medicines. You will see some of the strategic brands in the later slides. We are commercializing our products in more than 70 countries, and we are growing very nicely for the past several years. This is the FY 2026 financial results for the second quarter. We had a very nice second quarter results, and that led us to improve our guidance for the entire FY 2026.

For the revenue, we added JPY 110 billion to become JPY 2 trillion, JPY 3,300 billion revenue. Denominator is yen, so it is really hard to know. But more importantly, we revised our core operating profit as well for JPY 80 billion. We long have an aspiration to get to the core operating profit margin of 30% of the revenue, and we planned to achieve that in FY 2027, which is the next year. But we now anticipate that we can achieve that 30% core operating profit margin for this year. We are one year ahead of our plan. This is the outlook, longer term outlook of the company.

We have XTANDI, the prostate cancer treatment, more than $6 billion revenue, and we are facing the loss of exclusivity for XTANDI, already started, but majority of the LOE is starting in the U.S. August next year, and then Europe, then to Australia, Japan, Brazil, those other countries. We have been asked how we can manage that loss of exclusivity for $6 billion product, and our answer is that you can see the solid line in the middle of the slide, that is the growth has already started with five strategic brands, followed by the pipeline compounds that will reach the marketplace sometime 2029, 2030. The Corporate Strategic Plan 2026, as I mentioned, is a five-year strategic plan. The pipeline led self-funded growth to the sustainable growth mode in mid-2030s.

How you can do that, we are going to double the sales of the five strategic brands in the coming five years. Those five strategic brands are acquired or internally developed products, so we don't have to pay out significant parts of the revenue to third parties. We have a co-promotion arrangement with Pfizer for XTANDI, therefore we have to pay out 50% of the U.S. revenue back to Pfizer. For these five strategic brands, you don't have that kind of arrangement with third parties. Therefore, not only the contribution of the strategic brands will significantly increase from now to 2030, but that will result in better profitability structure of the company in 2030. So we are committed to make the 50% core operating profit before research and development.

That means, on the other hand, we will retain 30%, cost of goods and SG&A at 50% so that we can invest in 20% of the revenue into the R&D, but still secure 30% core operating profit after the 20% R&D. On top of that growth of the strategic brands, we have been successful managing the cost optimization using different methodologies, and we are almost achieved the committed JPY 150 billion annual recurring benefit until 2027. For the coming five years, including the JPY 40 billion in 2026 and JPY 45 billion in 2027, adding three more years under the Corporate Strategic Plan 2026, we are aiming to achieve JPY 200 billion annual recurring benefit in the coming five years. Therefore, it's the growth of the strategic brands, improvement of the profitability structure, adding cost optimization effort to generate JPY 200 billion more.

If you look at the left-hand side, the gray bars are the cumulative operating profit that we generated in the past five years, JPY 3.4 trillion. Under the revenue declining situation, the next five years, it's the red bars, we anticipate that we can generate JPY 4.3 trillion cumulative operating profit, which is bigger than the past five years, even though the revenue is declining for coming five years. Of those JPY 4.3 trillion, we are planning to invest JPY 2 trillion in the pipeline. We secured JPY 850 billion for strategic investments, including business development. On top of that, we secure JPY 750 billion for the dividend, which we are committed to increase every year, JPY 2 per share, continue to increase the dividend JPY 2 per share for the coming five years. To what we invest our JPY 2 trillion R&D, this is the pipeline.

We are committed to create the JPY 1 trillion revenue from our internal pipeline in mid-2030s. How you can do that? We want to initiate the pivotal or phase III clinical studies, 10+ clinical studies during the CSP 2026 five-year periods. Of that, five will be started this year and the next year. The red boxes are the progress in the first two quarters of this fiscal year. As you can see, we have already initiated two additional pivotal studies for ASP2138. We have declared a clinical POC for VIR-5500, now we call it ASP6958, for prostate cancer. We have moved forward several other new programs to clinical stage. So, it is not only something that we have scarce projects, but we have been intentionally creating the franchise of, for example, prostate cancer franchise, Claudin 18.2 franchise, ophthalmology disease franchise.

Even though we have been taking a focus area approach, which we start with the biology, then identify the modality to address that biology, and then finally, we figure out what disease is going to be the best value proposition for patients. But from this focus area approach, we have created four primary focuses, the triangle of biology, modality, and disease. Each triangle, we have been proving that each triangle can produce multiple projects from one triangle. So that creates the franchises. This is the key takeaway from the CSP 2026 and my very short presentation today. Our CSP 2026 is a pipeline-led, self-funding growth strategy for the coming years. We will maximize the value of the five strategic brands.

We have the robust pipeline that we can move to later clinical stage for five plus for the coming two years, and five more in the coming three years. How we can do it, we are going to have a very disciplined cash allocation policy. Lastly, but not least, we are improving the overall enterprise productivity so that we can deliver our CSP 2026. Thank you very much for your attention, and that is it.

Moderator

Thanks very much. I think we can go to Q&A. I have a few questions. Regarding your Claudin 18.2 strategy, I would like to talk about the bigger picture, but just for VYLOY in particular, it has been more successful, I think, than a lot of people anticipated. Why has it been a bigger seller than expected, and where do you see the potential for growing the demand for VYLOY?

Claus Zieler
Head of Commercial and Medical Affairs, Astellas

Yeah. Thanks, Steve. I think one of the challenges with the VYLOY launch was that we had to launch the test at the same time. This was not an established test. If we compare retrospectively, if we compare the acceptance of our testing, with HER2 back in the days, we have twice the penetration rate that HER2 achieved. We were extremely successful in penetrating the pathology market rapidly with the testing, and that gave us then a very good basis for identifying the patients that then would be able to receive VYLOY. Our testing rates are, at this point, 90% in Japan, 85% in Germany, U.S. a little bit behind with 75%. These are very, very high rates. Then, of course, you capture the patient population that is indicated for this treatment.

Moderator

The penetration on testing is already very high. What are the constraints on growth? What can you work on to expand demand even more?

Claus Zieler
Head of Commercial and Medical Affairs, Astellas

Well, I mean, you still have a modality that extends overall survival by about four months, so it's not insignificant. But at the same time, it comes with nausea and vomiting side effects in the first cycle. We had to develop a very, very meticulous protocol in how to manage those side effects. I think we've successfully rolled that out now across the different geographies. We've slowed down the dropout rate in the first cycles. That's been a major challenge in the early, let's say, in the first year of the launch, yeah. I think what we're continuing to work on is, what's the duration of therapy that patients would get over time? I think that data is not mature yet.

Moderator

Then the broader Claudin 18.2 strategy, you have two more assets in development. Could you talk about how you envisage your franchise building out?

Claus Zieler
Head of Commercial and Medical Affairs, Astellas

Sure. I do think we're well-positioned to be the leader in Claudin 18.2 for the next decade. The reason for that is, if you look at VYLOY really only is labeled for those Claudin 18.2 patients who have a 75% or higher expression rate. That's about 38%-40% of the gastric cancer population. The question is, what do we do with the low to medium expressers in gastric cancer? That's where we are now developing a bispecific antibody. We code name it ASP2138, which would then complement VYLOY. With ASP2138 in the low to medium expressers, VYLOY in the high expressers, we would then finally be able to cover the entire patient population which expresses Claudin 18.2. That would be the second asset that targets Claudin 18.2. Then we have a third asset that's an antibody-drug conjugate.

We code name it ASP546C, and that would be the first chemo-free treatment for the Claudin 18.2 segment. ASP546C would target the entire expression population. Not high or low, but across the entire spectrum. Imagine patients being able to go to patients, say, "There's finally a gastric cancer treatment which is free of chemotherapy." I think the value proposition would be very high if we could bring that to market. The three Claudin 18.2 assets that we have, VYLOY on the market, the other two in development, have very distinct positionings in the Claudin 18.2 space.

Moderator

ASP546C, this was an asset that you licensed in from Evopoint?

Claus Zieler
Head of Commercial and Medical Affairs, Astellas

That's correct.

Moderator

Could you maybe that's a nice segue into how you think about business development. In your plan over the next five years, you have a potential budget for $5.7 billion. Where do you see that investment best placed?

Naoki Okamura
CEO, Astellas

Thank you. Thank you for the question. We are pretty confident that we have a good business development team, and we will maintain our healthy appetite for those business development opportunities. What we do not do is, we call it rescue BD, which is cash for cash flow type of just exchange of the cash and cash flow. We want to have the assets that we can add value to with our expertise in the therapeutic area or technology platform that we have, or the pipeline that we already have, and add something to those pipeline, and we can add value to those additional asset. Those are the things that we want to pursue as the business development opportunities. To me, it doesn't matter the stage. Sometimes it is the clinical stage.

Most likely, we are pursuing the peri-PoC stage, just before the clinical PoC or just after the clinical PoC, because that is where we can add more value from the value creation standpoint. As I mentioned, we secured JPY 850 billion, including other strategic investments. On average, we can see JPY 100 billion per year for those business development opportunities. So we continue to be very opportunistic about the good assets.

Moderator

Right. So fairly agnostic about the potential size. Could be a string of JPY 100 billion deals.

Naoki Okamura
CEO, Astellas

Yes.

Moderator

A couple large ones.

Naoki Okamura
CEO, Astellas

We may use only JPY 50 billion in one year and then JPY 150 billion next year.

Moderator

Right.

Naoki Okamura
CEO, Astellas

You know.

Moderator

On your commercial strategy, Okamura-san, you talked about the franchises that you've built. You obviously have a very strong franchise in

Naoki Okamura
CEO, Astellas

Yeah

Moderator

Claudin 18.2.

Naoki Okamura
CEO, Astellas

Yeah.

Moderator

Developing one in ophthalmology. Could you just talk about the commercial thinking behind that approach?

Naoki Okamura
CEO, Astellas

Our focus area approach is sometimes seen as you never know where you are, because the disease comes at the last. But, of course, when we make the judgment, we have the current product portfolio, what is the strength in certain therapeutic areas. Therefore, that dictates the decision-making for the new pipeline assets. Therefore, it tends to become clustering into the franchise type things. One example is prostate cancer. One example is ophthalmology, retina diseases. But at the same time, for example, Claudin 18.2, which is the technology platform or the target, but it has expanded from gastric cancer to potentially pancreatic cancer. So, it is not simply defined as the therapeutic area strengths or simply the technology platform, like ADC.

We are doing the multi-pronged strategy for pipeline and creating an attractive franchise based on the patient's medical needs.

Moderator

Right. Actually, just going back to the Claudin 18.2. ASP546C, it's effective on patients with relatively low expression. Can you see a potential for it to be developed beyond gastric cancer?

Naoki Okamura
CEO, Astellas

Yes, we are running the pancreatic cancer trial as well. Because it's ADC,

sometimes high expression of the target is not required

Moderator

Right

Naoki Okamura
CEO, Astellas

to be active. Let's see what we can do for the pancreatic cancer.

Moderator

Mm-hmm. Maybe talk about some of your other very successful products. Obviously, PADCEV has been very successful. Could you talk about the outlook for PADCEV, please?

Claus Zieler
Head of Commercial and Medical Affairs, Astellas

Yeah. I mean, let's go back in time and remember when the data for the first-line metastatic urothelial cancer for PADCEV in combination with KEYTRUDA was presented. We received a standing ovation when we presented the data of doubling the overall survival of patients with urothelial cancer. So, with this agent, I think we've revolutionized the bladder cancer field or urothelial cancer field. We've very, very systematically built on top of that with this PADCEV-KEYTRUDA combination, taking it first from the first-line data that I just mentioned into what is called muscle-invasive bladder cancer. So it's the stage of the disease that comes just before the first-line metastatic disease. Muscle-invasive bladder cancer essentially divides into two parts, the so-called cisplatin-ineligible patients and the cisplatin-eligible patients. We've been able to show with two subsequent trials essentially the same results that we showed in the first-line metastatic patients.

Very consistent. I always call it the PADCEV hat trick, yeah? Because three trials in a row, three trials doubling overall survival, three trials with the same profile of efficacy versus side effects, yeah? This has led to speculation in the academic community, could we possibly use the PADCEV-KEYTRUDA combination as a bladder-sparing therapy, yeah? Just to recall, when you're diagnosed with bladder cancer, at some point, the cancer grows so far that your doctor will recommend a cystectomy, meaning the bladder has to be cut out, yeah? As you can imagine, for patients, that's a major impact on quality of life. So, physicians are extremely interested in, can we push that moment out in time, or can we maybe spare the bladder completely by extending the pre-surgical use of the so-called neoadjuvant use of PADCEV plus KEYTRUDA before the surgery takes place?

That's a trial we've now started. It will read out towards the end of the decade, and we're very excited to potentially take PADCEV one step further in the treatment of urothelial and bladder cancer.

Moderator

Okay. I think we're just about, well, we are out of time. Okamura-san, do you have any last words for the investment community?

Naoki Okamura
CEO, Astellas

No. Exactly this is the takeaway from my presentation today. Thank you very much for your attention. We will grow the strategic brands, reinvest in our pipeline, and using the very good cash allocation and improving the enterprise productivity. We will make the record high revenue in mid-2030s, and that's our aspiration for the next decade. Thank you.

Moderator

Thank you very much.